CM
FATE icon

Caption Management’s Fate Therapeutics FATE Stock Holding History

Caption Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57,000
Closed -$45K – 1605
2025
Q1 		$45K Buy
+57,000
New +$69.9K ﹤0.01% 1395
2021
Q4 		– Sell
-24,000
Closed -$1.42M – 1695
2021
Q3 		$1.42M Buy
24,000
+17,000
+243% +$1.33M 0.02% 904
2021
Q2 		$609K Buy
+7,000
New +$564K 0.01% 1002
2020
Q3 		– Sell
-15,300
Closed -$534K – 1101
2020
Q2 		$524K Sell
15,300
-31,400
-67% -$936K 0.02% 658
2020
Q1 		$1.04M Buy
46,700
+6,700
+17% +$169K 0.06% 394
2019
Q4 		$783K Buy
+40,000
New +$635K 0.03% 545

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caption Management's FATE Position: Q2 2025 in Review

Caption Management sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 57,000 shares — an estimated $45K sold.

Caption Management first reported a position in FATE in Q4 2019 and held it in 6 quarters. The position peaked at $1.42M in Q3 2021. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • Caption Management reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 57,000 Fate Therapeutics shares in Q2 2025, an estimated $45K.
  • Caption Management first reported a position in Fate Therapeutics in Q4 2019 and held it in 6 quarters.
  • Caption Management's Fate Therapeutics position peaked at $1.42M in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.